Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – What’s Next?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) saw an uptick in trading volume on Wednesday . 120,240 shares were traded during trading, a decline of 19% from the previous session’s volume of 149,343 shares.The stock last traded at $16.74 and had previously closed at $16.14.

Analysts Set New Price Targets

ALPMY has been the topic of several analyst reports. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Smbc Nikko Sec. raised Astellas Pharma to a “hold” rating in a report on Monday, February 16th. Finally, Jefferies Financial Group raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Astellas Pharma has an average rating of “Hold”.

Astellas Pharma Trading Up 4.0%

The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.23. The stock has a market cap of $30.53 billion, a P/E ratio of 14.18 and a beta of 0.15. The business’s fifty day simple moving average is $15.36 and its 200 day simple moving average is $13.29.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.29 by $0.15. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.21 billion. As a group, analysts expect that Astellas Pharma Inc. will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).